{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:07:11Z","timestamp":1789214831365,"version":"build-2803163510"},"reference-count":44,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"crossref","award":["SLS 591101"],"award-info":[{"award-number":["SLS 591101"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"crossref","award":["CAN2018\/316"],"award-info":[{"award-number":["CAN2018\/316"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6bergstiftelsen","doi-asserted-by":"crossref","award":["4-3584-2021"],"award-info":[{"award-number":["4-3584-2021"]}],"id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stiftelsen f\u00f6r kirurgiskt samarbete","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fatigue is a frequent and distressing symptom in patients with differentiated thyroid cancer (DTC) and may persist for years posttreatment, negatively impacting the quality of life. This study aimed to investigate predictors of long-term fatigue in DTC patients to identify patients who may benefit from early intervention to prevent fatigue and to examine whether thyrotropin (TSH) suppression is associated with fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This nationwide prospective study included 351 DTC patients treated with thyroidectomy and planned for radioiodine treatment during 2012\u20132017 in Sweden. Patients completed the Short Form-36 Health Survey (SF-36) and a study-specific questionnaire at inclusion and after 1, 3, and 5 years. Fatigue was assessed using the SF-36 vitality subscale. TSH values were retrieved from medical records. Fatigue 5 years after DTC treatment was predicted using linear regression with the following variables measured at 1 year: age, sex, education, number of comorbidities, body mass index (BMI), smoking, DTC risk, bodily pain, mental health, fatigue, sleep disturbance, change in view of life after diagnosis, and fear of cancer recurrence. The association between TSH and fatigue was studied using linear mixed models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In univariable linear regression analyses, significant early predictors of 5-year fatigue were a higher number of comorbidities, higher BMI, more bodily pain, worse mental health, more early fatigue, more sleep disturbance, a negative view of life following DTC diagnosis, and greater fear of cancer recurrence. Fatigue and poor mental health 1 year after DTC treatment were highly correlated (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.79) and therefore analyzed in separate multivariable models. In multivariable regression analyses, fatigue at year one remained a significant predictor of fatigue at year five (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      = 0.66,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). Worse mental health also remained a significant predictor of fatigue at year five (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      = \u22120.41,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). TSH was not a significant predictor of fatigue (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.161).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study found several predictors of long-term fatigue in DTC patients. One year after treatment, fatigue and poor mental health are particularly important predictors of long-term fatigue. TSH suppression does not explain fatigue in DTC patients. Identifying early fatigue and mental health issues in the clinic posttreatment is important, as patients may benefit from intervention to prevent long-term fatigue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10507256261479260","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:47:12Z","timestamp":1787132832000},"page":"1063-1073","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Long-Term Fatigue in Patients with Differentiated Thyroid Cancer: A Nationwide Prospective Study"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9873-6069","authenticated-orcid":false,"given":"Julia","family":"Winter","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden."},{"name":"R &amp; D Department, Stockholms Sjukhem Foundation, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erland","family":"Axelsson","sequence":"additional","affiliation":[{"name":"Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden."},{"name":"Liljeholmen University Primary Health Care Centre, Academic Primary Health Care Centre, Region Stockholm, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bonn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Ihre Lundgren","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden."},{"name":"Department of Breast, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bj\u00f6rkhem-Bergman","sequence":"additional","affiliation":[{"name":"R &amp; D Department, Stockholms Sjukhem Foundation, Stockholm, Sweden."},{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Hedman","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden."},{"name":"R &amp; D Department, Stockholms Sjukhem Foundation, Stockholm, Sweden."},{"name":"Institute for Palliative Care, Region Sk\u00e5ne, and Department of Clinical Science, Lund University, Lund, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_4_3_1","unstructured":"2.Lar\u00f8nningen SFJ Beydogan H Bray F et al. NORDCAN: Cancer incidence mortality prevalence and survival in the Nordic countries. 2022. Available from: https:\/\/nordcan.iarc.fr\/en\/dataviz\/survival_table?sexes=2&mode=period [Last accessed: October2 2023]."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1102965"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.741326"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.127"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2014.02.007"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1203"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0691"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0604"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-101"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0640"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1148-2"},{"key":"e_1_3_4_16_1","volume-title":"User\u2019s manual for the SF-36v2 Health Survey","author":"Maruish ME","year":"2011","unstructured":"15.Maruish ME. User\u2019s manual for the SF-36v2 Health Survey, 3rd ed. QualityMetric Incorporated: Lincoln, RI; 2011.","edition":"3"},{"key":"e_1_3_4_17_1","unstructured":"16.Tyreoideacancer Nationellt v\u00e5rdprogram. Regionala cancercentrum i samverkan; 2012."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0388"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:QURE.0000015290.76254.a5"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/03008916211025098"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7351.1417"},{"key":"e_1_3_4_23_1","volume-title":"SF-36 H\u00e4lsoenk\u00e4t: Svensk Manual och Tolkningsguide","author":"Sullivan M","year":"2002","unstructured":"22.Sullivan M, , Karlsson J, , Taft C. SF-36 H\u00e4lsoenk\u00e4t: Svensk Manual och Tolkningsguide, 2nd ed. Sahlgrenska University Hospital: Gothenburg; 2002.","edition":"2"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.11.013"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02158"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.4065\/77.4.371"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907x178757"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/08258597221131133"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2020.103707"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03116-z"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0587.2012.07348.x"},{"key":"e_1_3_4_32_1","unstructured":"31.Sk\u00f6ldk\u00f6rtelcancer Nationellt v\u00e5rdprogram Version: 3.1 2025-03-04. Regionala cancercentrum i samverkan; 2025."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0015"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1084-3612(03)00049-2"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34746"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/POR.S130510"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2018.03.026"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu9091003"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-020-01021-7"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0541"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.79071"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0277"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0052"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153657"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1230-2"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261479260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10507256261479260","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261479260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:16:48Z","timestamp":1789211808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10507256261479260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1177\/10507256261479260"],"URL":"https:\/\/doi.org\/10.1177\/10507256261479260","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}